NEURONES: The Margin Recovery Is Real — Now It Depends on What You Pay

NEURONES (NRO) reported first-half 2026 results on September 9 that quietly answer the question that hung over the stock all of 2025: can this French IT services firm grow without giving up profit? The headline is a 6.9% net margin for the half, up from 6.3% a year earlier. What matters more is how it got there — growth accelerated and every profit line expanded at the same time.

Revenue for the half came to €454.8 million, up 7.2%, with fully 6.9% of that organic. Growth sped up through the period: 5.6% organic in the first quarter, then 8.0% in the second. The operating margin rose to 8.7% of revenue from a squeezed 7.8% a year before. Both numbers carry the story, because last year they moved in opposite directions.

That tension was the bear case. In 2025 NEURONES grew revenue 5.8% to €857.2 million, yet its operating margin fell 80 basis points to 9.6%, net profit stayed flat at €52.1 million, and free cash flow dropped more than 16%. It was the classic services-company problem: sales climbing while the bottom line refuses to follow, as wage and rate pressure ate the difference. A lot of investors read that as a maturing business whose growth had stopped translating into earnings.

The first half of 2026 is the evidence that the squeeze was cyclical, not structural. The steps up in data work, digital projects, ServiceNow (ITSM) engagements, and business-process management carried the accelerated growth, and the margin expansion shows the pricing and utilization stress of 2025 eased. Management also folded agentic-AI work into client projects and internal processes — real billable demand here, not just a slide-deck phrase. On this footing, the company raised its full-year revenue guidance to over €900 million while holding its operating-margin target near 9%.

So the operating case improved measurably. The question the stock forces is whether you have to pay up for it. NEURONES trades around €35–36, roughly 17 times trailing earnings, with a dividend yield of about 3.8%. That is not a cheap IT-services multiple relative to European peers — it is roughly fair, maybe a touch above. What softens the price is the balance sheet: a net cash position of roughly €337 million, close to a third of the company's market capitalization, sitting behind a cash-generative, family-controlled business that has paid and grown a dividend for years.

This is where the honest read separates the company from the stock. The business just proved it can grow and expand margins together again, and its net cash gives it unusual downside protection for a services firm. But the market never repriced the shares to reflect the 2025 doubt — the recovery is now reflected in a multiple that sits at peer level rather than below it. You are not buying a reset; you are paying a reasonable price for a compounder that is emerging from a rough patch.

The proof that the margin recovery is durable, not just one favorable half, lands in the next two to four quarters: the third- and fourth-quarter revenue prints to confirm growth stays in the high single digits, and the full-year 2026 results next March to see that ~9% operating margin actually arrives. If growth holds and the margin target is met, the fair multiple has room to work. If the acceleration fades and margins slip again, the stock has less cushion than the yield suggests. At this price, NEURONES is worth owning — or at least watching closely — as a quality compounder, but it is not a bargain that rewards chasing.